Get Premium to unlock powerful stock data
FRA:7OC (USA)  
OncoCyte Corp logo

OncoCyte Corp

€ 0.82 (-4.12%) Jun 29
P/E:
At Loss
P/B:
1.46
Market Cap:
€ 102.08M ($ 106.51M)
Enterprise V:
€ 86.89M ($ 90.66M)
Volume:
-
Avg Vol (2M):
4.10K
Also Trade In:
Volume:
-
Market Cap €:
102.08M
Market Cap $:
106.51M
PE Ratio:
At Loss
Avg Vol (2-Month):
4.10K
Enterprise Value €:
86.89M
Enterprise Value $:
90.66M
PB Ratio:
1.46
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Name Current Vs Industry Vs History
Cash-To-Debt 4.1
Equity-to-Asset 0.39
Debt-to-Equity 0.09
Debt-to-EBITDA -0.08
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.66
Distress
Grey
Safe
Beneish M-Score 0.72
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 22.37
9-Day RSI 29.16
14-Day RSI 33.54
6-1 Month Momentum % -48.9
12-1 Month Momentum % -80.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.76
Quick Ratio 1.76
Cash Ratio 1.5
Days Inventory 13.13
Days Sales Outstanding 57.47
Days Payable 72.64

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -31.4
Name Current Vs Industry Vs History
Gross Margin % -5.28
Operating Margin % -637.81
Net Margin % -877.9
ROE % -81.78
ROA % -45.12
ROIC % -42.3
ROC (Joel Greenblatt) % -868.96
ROCE % -50.7

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 10.22
PB Ratio 1.46
EV-to-EBIT -1.26
EV-to-EBITDA -1.35
EV-to-Revenue 11.31
EV-to-Forward-Revenue 10.19
EV-to-FCF -2.14
Earnings Yield (Greenblatt) % -79.37

Financials (Next Earnings Date:2022-08-10 Est.)

FRA:7OC's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 6.991
EPS (TTM) (€) -0.673
Beta 0.18
Volatility % 58.45
14-Day RSI 33.54
14-Day ATR (€) 0.045433
20-Day SMA (€) 0.98525
12-1 Month Momentum % -80.79
52-Week Range (€) 0.815 - 5
Shares Outstanding (Mil) 118.51

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

OncoCyte Corp Filings

Document Form Filing Date
No Filing Data